Welcome to this next fireside chat with BlossomHill Therapeutics. With us today, we have Jean Cui, President and CEO, as well as Geoff Oxnard, Chief Medical Officer. Jean and Geoff, welcome. Thanks for joining us today. Thanks. For those investors who are meeting BlossomHill for the first time, what is the idea behind your macrocyclic design approach, Jean, and how does the team's experience in building Turning Point Therapeutics, and other companies perhaps, shape how you choose targets and run the company?
Yeah. Thanks for the opportunity. BlossomHill Therapeutics, and I am the scientific founder, and also by training is a chemist. For the macrocyclic is a commonly used tool for medicinal chemists, to achieve the greater activity and also the PK profile. For the kinase, that is the one we are talking about, the overcome resistant, it is the requirement, at a later generation, it is high. First, to overcome resistant, I work on the lorlatinib and repotrectinib. BlossomHill Therapeutics, it is BH-30643. Developers, the idea is that from the later generation. Later generation, first, need to overcome resistant. Secondly, need to be actually more potent against the original mutation compared to the previous molecules, like TAGRISSO, if we work on the EGFR.
How to overcome this and to achieve the super-potency, then look at the mutation. Basically, for kinase and resistant mutation, it is two type. One is actually enable ATP binding much tightly, the other is disable the binding of the inhibitor, like TAGRISSO, C797S resistant. Make the molecule to be super-potency against the original primary mutation, and also potentially all of the reported resistant mutation, definitely we need to target ATP center. At ATP center, this macrocyclic structure is really allow us through the three-dimensional interaction, very precisely interaction with the ATP center to achieve this super-potency.
As lorlatinib and also repotrectinib, now it is BH-30643, we achieved the expected for the 643, we achieved the sub-nanomolar activity against the primary mutation and classical mutation for EGFR, exon 19 deletion, L858R. The molecule also, this is the potency is 10-fold more potent compared to the TAGRISSO. Also, it is equipotent, very important, equipotent sub-nanomolar against the compound resistant mutation. At the same time, it is also very potent against the atypical mutation and exon 20 insertion, without resistant liability. For EGFR, we also need to have the greatest selectivity window against the wild-type EGFR. To tackle this macrocyclic design, allow us actually to capture the active conformation that is shared with the mutant EGFR, because it is active conformation there.
The wild-type EGFR prefer, and the opened and the inactive confirmation, we start, and the macrocyclic design will allow us have great selectivity window also against the wild-type EGFR.
Okay. Yeah. Maybe a few follow-up questions on BH-30643, the EGFR program. I understand, as you mentioned, it really binds to all of these different mutations, including the classical mutations that TAGRISSO targets. The initial opportunity, I believe, that you're pursuing is in the C797S mutation population specifically. Yeah, maybe describe to us sort of the unmet need in the C797S opportunity and the sort of the size of that market, and also what are you doing here with BH-30643?
Mm-hmm. I will start, and then later Geoff will have the more input on this. C797S was reported 10 years ago, back to 2015, and Geoff is working at Dana-Farber time and report this C797S resistance. For past 10 years, a lot of effort tried to overcome this resistance. However, kind of for the not very successful, the original effort, back to the first generation, we know gefitinib are the modification of the first generation and second generation, be able to achieve some of the transient effect on the cell overcome C797S resistance. However, it is only last for three or four months. Very important, it is kind of for the need also to have the more durable response and need also to be super potent against original primary mutation.
Our BH-30643, I think is the very first molecule achieved the tenfold more potent than TAGRISSO and also C797S. What is the patient population again for the C797S? We think kind of, we know the C797S is a later event in term of the resistance compared to the MET amplification, that is early event. With most recent publication, several publication indicate it's about 13% of patient develop C797S after TAGRISSO resistance. That will represent about at U.S. yearly, it might have about kind of 300- 3,200 patient, and kind of worldwide is 16,000 for C797S resistant. Geoff?
Michael, you asked what is the unmet need. I think there are a lot of cancers now where a patient has multiple targeted therapies in their disease course. You see this in ALK, you see this in ER-positive breast cancer, prostate cancer. In EGFR mutant lung cancer, after first-line targeted therapy, patients, and again, I am a lung cancer doc still seeing these patients are on chemo and they are living like a lung cancer patient, and they are not having that experience. Patients are motivated to have a targeted therapy option, and when we look at that later line space, there are a lot of therapies evolving in that space, but none of them have that targeted therapy backbone, and a lot of them have burdensome toxicity.
While I am excited about the progress and the emergence of large molecules, et cetera, I also know that what patients want is a pill. To be able to offer that to patients is very meaningful. To be able to do that with a tolerable oral therapy, with an efficient single-arm development path is a clear path to get this medicine efficiently launched and sort of pave a path then for further development beyond.
Right. You just recently presented some updated data at World Lung on the C797S cohort of the program. Remind us of what the takeaways are from that and how that sort of further validates the molecule.
Great. We shared data at World Lung in 40 patients with C797S resistance, 45% response rate. We see responses are confirming, really all of our responses are confirming. We are not seeing transients, which is something that prior medicines have seen because of resistance escape. We do not see that escape. We see durability. We have had patients on responding for more than 15 months. It is coming together like a profile of medicine that could support accelerated approval, aiming for that to beat sort of that 40% response rate bar that prior medicines have had to beat. We see a really patient-centered safety profile, a low burden of wild-type toxicities, 8% or 9% of patients with dose reduction, 3% of patients coming off due to toxicity.
Really a profile that we think supports accelerated approval, that is exactly the dataset that we took to the FDA for our end of phase I meeting to talk about next steps for development.
Right. In this post-osimertinib setting right now, how are these patients typically treated and what is the bar for an accelerated approval in this space?
Sure. Some of those patients were enrolling having received multiple lines of therapy. We have had patients enrolled after 12 lines. It is actually a pretty sick, high brain met burden population we have been enrolling. So many of those patients are facing single agent chemotherapies where a response rates bar is maybe 10% or maybe it is 23% if you consider docetaxel ramucirumab, which is not adopted much. Clearly that is a bar this medicine can exceed. In patients who are TKI-naive, having received osimertinib, there are second line regimens approved, chemo amivantamab, 53% response rate, sort of six-month median PFS, maybe chemo ivonescimab coming soon, maybe ADCs coming soon. These are all meaningful advances, but we see great enrollment of patients who would rather be on a pill instead of having to receive chemotherapy.
Clearly that need is not fully addressed by a chemotherapy, but it does mean that if there is a regimen out there with a 50% response rate, we need to emulate that response rate with better safety, better durability, if we want this phase II trial to build towards a dataset that we could submit for accelerated NDA. But that is certainly, that was a whole part of the dialogue at our end of phase I, and the overall package looks like a package that can move towards an accelerated approval path, that is what we are planning to kick off Q1 next year with this SOLARA-2, which is the phase II portion of our ongoing phase I/II trial.
Yeah. Maybe just talk about this a little more. So fresh off the press, you had the FDA meeting this week, I think, or you announced it
Yep
earlier this week. What were the key takeaways from that?
The first thing you want at one of these meetings is you want a dose, and you want it efficiently. Dose optimization has been a little bit burdensome for biotech. You could spend a lot of time enrolling patients across a lot of doses. We've seen phase III trials in the EGFR space where you've needed to have lots of patients treated at lots of doses. We wanted to get to a dose quickly so we can move efficiently forward. We're glad that this medicine has a lot of exposure, and so at 50 mg BID, which is our RP2D, this medicine exceeds the exposure of osimertinib, and it's a medicine that's 10 times more potent than osimertinib. We feel good about the kind of exposures we're getting at this dose, and it's got a very patient-centered safety profile, without burdensome wild-type toxicity.
We really had no challenges in aligning on a dose with the FDA and allowing us to move forward with late phase development. The second key question is this a clinical package that could support a single arm registrational development? The answer is yes. We're moving forward with the pivotal phase II, and that will be starting Q1 next year, understanding that trial needs to meet these efficacy benchmarks in order to then be able to support an NDA.
Right. How long do you think it will take to enroll the phase II study until you actually may have a data readout from that?
Yeah, we haven't totally assembled that projection yet, except to say that this is a seamless plan. We have an ongoing trial in 40 sites, 10 countries, so we're ready to use all of that building towards phase II kickoff Q1. We're going to be adding China, which we think will support enrollment efficiently next year as well. We think we can sustain our momentum, which has enrolled efficiently so far, in order to get this done in an efficient timeframe.
Right. You did announce this collaboration with Foundation Medicine as well. How important is that to facilitate this study?
Really, the study is building off of the latent presence of resistance testing, which is everywhere. The patients out there are getting this testing. They're getting it even more today compared to a quarter ago because we just heard about the savolitinib data, which is targeting MET for resistance. So resistance testing is a reality, and we are just building off of the prevalent testing in the U.S., in Japan, Korea, Taiwan, Hong Kong. The Foundation Medicine CDx relationship, I think, will help catalyze that even further. Really, that is a critical regulatory partnership so that when the time comes for an NDA, we have a well-established and validated assay that can support registration with a CDx partner.
Okay. I think one of the hypothesis behind the molecule is that it can drive much longer duration of response by hitting all of the mutations. How important is read-through from that cohort as we get more updates next year in terms of durability for some of the other opportunities that you are pursuing with the molecule?
Yeah. I think an EGFR patient looks at an ALK patient and says, "Wow, they can get so much distance out of alectinib or lorlatinib. Why can't I have that?" We think with a great EGFR inhibitor, some patients should be able to have really long durations of benefit. I agree with you. The first read on that is from C797S. As Jean mentioned, this is the later resistance. This is the sort of on-target resistance that occurs two or three years into osimertinib therapy. Our thesis is that if you can convert those back into responses, they can be on medicine for a long time. So far, we have seen responses lasting with patients out 15 months. That durability will be assembled with an update first half of next year.
As opposed to MET resistance, which can be more aggressive, we do think this is the kind of resistance that can allow some patients to be on a pill, sparing chemotherapy for a long time. Yeah, we hope to have that data, or you can expect to have that data first half next year.
Okay.
Also kind of from the biology point, this is beyond the kind of for the longer duration of the response and not only for C797S subpopulation, we can overcome this subclone. If we look at the kind of at the very beginning and hit the cancer cell tough and surprise them, because this is why we emphasize, that is learning from the lorlatinib and repotrectinib. It is a more potent molecule by is use the frontline, and it surprise the cancer cell is much tougher. It take a longer time actually to develop and resistant. This is kind of the and this is definitely the stage before the C797S mutation developer. Yeah.
Hmm. This is a pretty good segue to my next question. So another much bigger opportunity that you are pursuing is obviously in the frontline classical mutation setting, right? So that is the approved TAGRISSO indication, which some think is a high bar. You have already reported some response data. It looks similar to TAGRISSO, right? Monotherapy in frontline patients. I guess how much confidence can we have that in the first-line setting, this could really extend duration beyond the high teens sort of PFS rates that we see with TAGRISSO?
The data is evolving. We know the kind of, and it is expected to have the objective response rate similar compared to the TAGRISSO because that is pretty much reflect the heterogeneity of the cancer, the patient population there. Most important is durability, is going to take time to get the final answer there. This is why we want to actually to demonstrate the capability of the molecule, design our expansion cohort early time to enroll the patient that is TKI-naive patient. Next year, we still kind of premature, it may take even longer time to read out the result. However, if we look at the current landscape for EGFR, not only the frontline, TAGRISSO is really doing great.
However, we want to see what is the biology allow us to target EGFR, is that opportunity for biology point get more potent molecule can even give the longer duration of the response. Also in the kind of the resistant population, after TAGRISSO resistance, we know a lot of ADCs now currently demonstrate great activity. However, EGFR mutation is the backbone for this subpopulation, non-small cell lung cancer, even with resistant EGFR backbone, if you look at the circulating DNA, the mutation still there play important role. So it is important to have the next generation EGFR inhibitor as the key backbone, not only for the front line, also for the resistant population. Of course, need the type in to combination with other modalities there. Yeah.
We have three efforts, I would say, ongoing in parallel. One, we are characterizing first-line signal, both in classical, atypical, and exon 20. All that, each of those is an area where we have seen activity of this medicine. Second, we have initiated combination development. We have a chemo combination now in dose escalation. The medicine does not have cytopenias. We think we will combine cleanly with chemotherapy and allow other combinations beyond. Finally, we are watching the space to where the unmet need is greatest, and I would say that is even a little different this year than last year. What we think is over the coming year, it will be clear where the most efficient and highest ROI phase III destiny for this medicine is.
Right. I mean, some investors wonder that given that C797S is, it's been a relatively small proportion of resistance to osimertinib, as you said, 10%-13%. How much confidence can we have that BH-30643 can indeed overcome osimertinib resistance and really extend PFS out, just given that there are a lot of other things that are going on sometimes as you think about people progressing?
Yeah. So this is a great question, especially after TAGRISSO resistance, even so C797S detected, and quite often is also co-existing with other resistant mechanism. This is exactly, for the TAGRISSO used at the second line and overcome T790M, it only achieved about eight to nine months or 9-10 months PFS there, and it's co-existing together. So that is the kind of for certain patient is more durable, for certain patient is shorter. However, as a monotherapy, it is very important for the molecule get monotherapy approved to demonstrate the capability, and then patient will have a choice and have kind of as a monotherapy treatment, and also later we also develop a combination modalities there. Yeah.
Okay. So, all right. So just remind us of the updates that are coming up for the molecule next year, throughout the year.
Yeah. That is kind of for the C797S in the first half of next year. We will update our phase I data. That means kind of there will be more than 40 patients, more patients, and also most important, what is the durability look like. That will give us more accurate prediction on how the phase II study is going to look like. We expect to enroll the phase II patient in the first half 2027 and have the really kick out phase II study there. Our combination with chemotherapy is ongoing. We will report initial data in terms of safety and also the cancer activities there in the second half 2027. Also, we will first disclose our naive cohort in the classical mutation, naive cohort, in terms of efficacy and durability.
Okay.
Yeah, second half 2027.
Okay. I did want to spend a couple minutes touching on your CLK inhibitor program. I saw an abstract in it at ASH in a few weeks. Just remind us where you are with the CLK program and how investors should think about the program unfolding next year.
Yes, CLK is a very exciting project. This is novel mechanism and target alternative splicing, aberrant alternative splicing. The really kind of for the, from the what we preclinical study and the molecule, is potentially overcome and general and resistant mechanism, no matter is the chemotherapy, is a blood cancer, or it is solid tumor, potentially, combined with standard therapy and enable the molecule to kind of for the response longer, because it is a target DNA repair pathway and apoptosis pathway, and also metabolic switch there. Currently, our first clinical application in the high-risk MDS and also the refractory relapse AML patient population. We pretty much finished dose escalation and then select the dose level to secure, to have the more accurate and understand the efficacy.
We do observe the complete remission in the combination with venetoclax and also in high-risk MDS as the monotherapy there. This is indicated this new mechanism and is kind of the play certain role there. We are now in the stage, we will present some of the data at the ASH coming, and understand what is the mechanism behind for the patient achieve the complete remission there. At the same time, we also expand the study to the myelofibrosis as a monotherapy, and also expand our combination to the triple combination with the azacitidine and venetoclax as the standard therapy there.
Okay.
A question on your pan-KRAS program. Obviously, a lot of success in the KRAS space in general with the Revolution Medicines RASONQUE approved now. A lot of mutation-selective inhibitors advancing, especially 12C and D inhibitors. I think in generally, industry has been less successful with generating pan-KRAS inhibitors, but you have an interesting program approaching phase I. What can you tell us about 1284?
For our pan-KRAS inhibitor, definitely, at this stage, any of the molecule goes to clinic and needed to have the kind of a goal actually to kind of solving certain and medical need. That means needed to actually to beyond the divarasib and the tri-complex molecule. We do believe tri-complex molecule have certain limitations, such as kind of the molecule from mechanism point cannot completely shut down the GTP, GDP, and the cycling there. This is a potential will impact the durability of the treatment there. The switch II pocket inhibitor beyond KRAS G12C and it encounter some of the druggability issues, and then our bioavailability is low in the clinic and need the dose very high.
To solving this issue, we want to leverage actually the success of the covalent molecule KRAS G12C. That is very successful, especially the divarasib and the covalent KRAS G12C molecule there. We start and kind of we have the new novel chemical scaffold and designed to focus on the induce the conformation change on the KRAS G12C and KRAS protein makes the surface not available to have the tight interaction with effectors, potentially complete shutdown the cycling there. So we introduce the concept of pseudo-irreversible, so that will mimic pharmacology point, will mimic the covalent KRAS G12C molecule. So we start and we achieve the long residence time in KRAS G12V and D and C, and also the other mutation there have the selectivity over the HRAS and NRAS there.
Indeed, also the molecule behave very similar compared to covalent molecule. That is we achieved the prolonged inhibition of the KRAS signaling, allow us to have the low dose level to achieve the deep tumor regression in the KRAS G12V and D and C and other mutant the tumor model there. So we hope that will kind of in the clinic achieve the similar what we achieved in pre-clinic. We are kind of on schedule for IND submission first quarter 2027.
Okay, great. Well, thank you, Jean and Geoff. Time's up. Really appreciate all the updates and congrats on the progress.
Yeah.
Appreciate it.
Thank you.
Thank you.